Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2024)
Stoke Therapeutics' quarterly Gains from Sales and Divestitures came in at $93000.0 in Q4 2024.
Stoke Therapeutics has reported Gains from Sales and Divestitures for 1 years, with the latest figure at $93000.0 in Q4 2024.
- For the quarter ending Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $93000.0; the trailing twelve-month figure through Dec 2024 stood at $93000.0 (changed N/A YoY), and the FY2024 full-year result was $93000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q4 2024 stood at $93000.0.
- The five-year high for Gains from Sales and Divestitures was $93000.0 in Q4 2024, with the low at $93000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 93,000.00 |
| Dec 31, 2024 | 93,000.00 |